WHAT IS CLAIMED IS:

1. A method for treating acute ischemic stroke in a human comprising administering tenecteplase to the human in a total dose of about 0.05 to 0.5 mg/kg, given as (a) an initial bolus dose of about 0.05 to 0.15 mg/kg, followed by infusion of an amount equaling the total dose minus the initial dose over a period of about 50-90 minutes, or (b) a bolus.
2. The method of claim 1 wherein the total dose is about 0.2 to 0.3 mg/kg.
3. The method of claim 1 or 2 wherein the total dose is about 0.25 mg/kg.
4. The method of any one of claims 1-3 wherein the total dose is given as an initial bolus followed by the infusion.
5. The method of any one of claims 1-4 wherein the initial dose is about 0.08 to 0.12 mg/kg bolus.
6. The method of any one of claims 1-5 wherein the initial dose is about 0.1 mg/kg bolus.
7. The method of any one of claims 1-6 wherein the period of infusion is about 55-70 minutes.
8. The method of any one of claims 1-7 wherein the period of infusion is about 60 minutes.
9. The method of any one of claim 1-8 wherein the total dose is about 0.25 mg/kg, given as an initial bolus of about 0.1 mg/kg, followed by infusion of about 0.15 mg/kg over about 60 minutes.
10. The method of any one of claims 1-3 wherein the total dose is given as a bolus.
11. The method of any one of claims 1-10 wherein the tenecteplase is administered to the human at a time between about 15 minutes and 20 hours from the onset of acute ischemic stroke.
12. The method of any one of claims 1-11 wherein the tenecteplase is administered to the human at a time between about 30 minutes and 6 hours from the onset of acute ischemic stroke.
13. The method of any one of claims 1-12 wherein the tenecteplase is administered to the human at a time between about 30 minutes and 3 hours from the onset of acute ischemic stroke.
14. The method of any one of claims 1-13 wherein the bolus is intravenous.

15. The method of any one of claims 1-14 further comprising administering to the human an effective amount of a second medicament, wherein the first medicament is tenecteplase.
16. The method of claim 15 wherein the second medicament is a neuroprotective agent, a thrombolytic agent, a glycoprotein IIb IIIa antagonist, or an anti-CD18 antibody.
17. A kit comprising:
    (a) a container comprising tenecteplase; and
    (b) instructions for using the tenecteplase to treat acute ischemic stroke in a human by administering the tenecteplase to the human in a total dose of about 0.05 to 0.5 mg/kg, given as (a) an initial bolus dose of about 0.05 to 0.15 mg/kg, followed by infusion of an amount equaling the total dose minus the initial dose over a period of about 50-90 minutes, or (b) a bolus.
18. The kit of claim 17 wherein the total dose is about 0.2 to 0.3 mg/kg.
19. The kit of claim 17 or 18 wherein the total dose is about 0.25 mg/kg.
20. The kit of any one of claims 17-19 wherein the total dose is given as an initial bolus followed by the infusion.
21. The kit of any one of claims 17-20 wherein the initial bolus dose is about 0.08 to 0.12 mg/kg.
22. The kit of any one of claims 17-21 wherein the total dose is about 0.25 mg/kg, given as an initial bolus of about 0.1 mg/kg, followed by infusion of about 0.15 mg/kg over about 60 minutes.
23. The kit of any one of claims 17-19 wherein the total dose is given as a bolus.
24. The kit of any one of claims 17-23 further comprising a container comprising a second medicament, wherein the instructions include instructions for using the second medicament in combination with the tenecteplase to treat ischemic stroke in a human by administering to the human an effective amount of the second medicament.
25. The kit of claim 24 wherein the second medicament is a neuroprotective agent, a thrombolytic agent, a glycoprotein IIb IIIa antagonist, or an anti-CD18 antibody.

WHAT IS CLAIMED IS:

1. Use of tenecteplase in the manufacture of a medicament for treatment of acute ischemic stroke in a human, wherein the treatment comprises administering tenecteplase in a total dose of 0.05 to 0.5mg/kg, given as an initial bolus dose of 0.05 to 0.15 mg/kg, followed by infusion of an amount equaling the total dose minus the initial dose over a period of 50-90 minutes.

2. Use of tenecteplase according to claim 1 wherein the total dose is 0.2 to 0.3 mg/kg.

3. Use of tenecteplase according to claim 1 or 2 wherein the total dose is 0.25 mg/kg.

4. Use of tenecteplase according to any one of claims 1-3 wherein the initial dose is 0.08 to 0.12 mg/kg bolus.

5. Use of tenecteplase according to any one of claims 1-4 wherein the initial dose is 0.1 mg/kg bolus.

6. Use of tenecteplase according to any one of claims 1-5 wherein the period of infusion is 55-70 minutes.

7. Use of tenecteplase according to any one of claims 1-6 wherein the period of infusion is 60 minutes

8. Use of tenecteplase according to any one of claims 1-7 wherein the total dose is 0.25 mg/kg, given as an initial bolus of 0.1 mg/kg, followed by infusion of 0.15 mg/kg over 60 minutes.

9. Use of tenecteplase according to any one of claims 1-8 wherein the tenecteplase is administered to the human at a time between 15 minutes and 20 hours from the onset of acute ischemic stroke.

10. Use of tenecteplase according to any one of claims 1-9 wherein the tenecteplase is administered to the human at a time between 30 minutes and 6 hours from the onset of acute ischemic stroke.

11. Use of tenecteplase according to any one of claims 1-10 wherein the tenecteplase is administered to the human at a time between 30 minutes and 3 hours from the onset of acute ischemic stroke.

12. Use of tenecteplase according to any one of claims 1-11 wherein the bolus is intravenous.

13. Use of tenecteplase according to any one of claims 1-12 further comprising administering to the human an effective amount of a second medicament, wherein the first medicament is tenecteplase.

14. Use of tenecteplase according to claim 13 wherein the second medicament is a neuroprotective agent, a thrombolytic agent, a glycoprotein IIb IIIa antagonist, or an anti-CD18 antibody.

15. A kit when used according to any one of claima 1-14, the comprising tenecteplase.

16. The kit of claim 15 further comprising a second medicament, wherein the first medicament is tenecteplase.

17. The kit of claim 16 wherein the second medicament is a neuroprotective agent, a thrombolytic agent, a glycoprotein IIb IIIa antagonist, or an anti-CD18 antibody.